Photobiomodulation for Dry Age-Related Macular Degeneration
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)
Recruiting
Observational Study
Dry Age-related Macular Degeneration
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Sex
Any
Study type
Observational
Participants needed
500 (estimated)
Sponsor
LumiThera, Inc. · Industry
Who this trial is looking for
This trial is looking for adults with dry age-related macular degeneration. By participating, you will help researchers collect information about the safety and effectiveness of a light treatment used for this condition.
Are You a Good Fit for This Trial?
You may be able to join if
I have been diagnosed with dry age-related macular degeneration.
I can communicate well and understand what the study involves.
I have given my written consent to take part in the study.
You may not be able to join if
I have geographic atrophy that involves my center of vision.
I have neovascular maculopathy.
I have used any light-activating medications in the past 30 days without consulting my doctor.
I am known to be sensitive to yellow light, red light, or near infrared light.
I have a history of light-activated central nervous system disorders.
I am unlikely to follow the study guidelines according to the investigator.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with dry age-related macular degeneration (AMD) in routine clinical practice. Data will be collected retrospectively and prospectively.
PBM involves the use of visible light …
The purpose of this registry study is to collect real life data pertaining to the safety and clinical effectiveness of multi-wavelength photobiomodulation (PBM) as provided by the Valeda Light Delivery System in participants with dry age-related macular degeneration (AMD) in routine clinical practice. Data will be collected retrospectively and prospectively.
PBM involves the use of visible light to near infrared light (NIR) (500-1000 nanometers) produced by a laser or a non-coherent light source applied to the surface of the body to activate mitochondrial respiratory chain components, stabilize metabolic function, and promote cellular proliferation.
This registry study will be conducted in Europe, the US, and select other countries approved by their regulatory agency.
This registry study was initiated as a combined retrospective and prospective data collection effort. After the acquisition of LumiThera by Alcon Research, LLC in September 2025, the study was amended to prospectively collect data from U.S. sites starting in July 2026.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
1. Diagnosis or confirmation of diagnosis of dry AMD disease by Investigator;
2. Able to communicate well with the Investigator and able to understand and comply with the requirements of the study;
3. Informed of the nature of this study and has provided written, informed consen…
Inclusion Criteria:
1. Diagnosis or confirmation of diagnosis of dry AMD disease by Investigator;
2. Able to communicate well with the Investigator and able to understand and comply with the requirements of the study;
3. Informed of the nature of this study and has provided written, informed consent; (participants enrolled retrospectively will need to be contacted and sign an informed consent form prior to their data being used).
Exclusion Criteria:
* US Sites Only: Center-involving geographic atrophy;
* Neovascular maculopathy;
* Use of any photosensitizing agent (e.g. topicals, injectables) activated by the Valeda Light Deliver System within 30 days prior to treatment without consulting participant's physician;
* Known photosensitivity to yellow light, red light, or near infrared radiation (NIR), or has a history of light activated central nervous system disorders (e.g. epilepsy, migraine);
* In the opinion of the Investigator, is unlikely to comply with the study protocol or has a history or current evidence of any condition that, in the opinion of the investigator, might interfere with the participant's involvement in the trial, or is not in the best interest of the participant.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.